Nina Radosevic-Robin
Overview
Explore the profile of Nina Radosevic-Robin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1442
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giro A, Passildas-Jahanmohan J, Kossai M, Bidet Y, Molnar I, Bernadach M, et al.
Anticancer Res
. 2024 Oct;
44(11):4983-4994.
PMID: 39477319
Background/aim: Triple-negative breast cancer (TNBC) is the most heterogeneous breast cancer subtype, posing numerous challenges in clinical decision-making. Biomarkers are essential to personalize management of TNBC patients. While tumor infiltrating...
2.
Radosevic-Robin N, Kossai M, Penault-Llorca F
Transl Breast Cancer Res
. 2024 May;
4:28.
PMID: 38751472
Technologies allowing tissue molecular analysis of the "high-plex" type (>20 molecules per tissue section) are the 21 century inventions that are revolutionizing our knowledge of the biology of malignant tumors...
3.
Adam J, Le Stang N, Uguen A, Badoual C, Chenard M, Lantuejoul S, et al.
Mod Pathol
. 2023 Apr;
36(8):100192.
PMID: 37084942
Pan-Trk immunohistochemistry has been described as a screening test for the detection of NTRK fusions in a broad spectrum of tumor types. However, pan-Trk testing in the clinical setting may...
4.
To N, Gabelle-Flandin I, Luong T, Loganadane G, Ouidir N, Boukhobza C, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046691
Background: Radiation therapy (RT), a novel approach to boost the anticancer immune response, has been progressively evaluated in the neoadjuvant setting in breast cancer (BC). Purpose: We aimed to evaluate...
5.
To N, Kossai M, Ouidir N, Grellier N, Assaf E, Gabelle-Flandin I, et al.
Rep Pract Oncol Radiother
. 2023 Jan;
27(6):1114-1118.
PMID: 36632297
No abstract available.
6.
Veyssiere H, Bidet Y, Penault-Llorca F, Radosevic-Robin N, Durando X
Clin Proteomics
. 2022 Jul;
19(1):25.
PMID: 35818030
Breast cancer (BC) is the most common cancer and among the leading causes of cancer death in women. It is a heterogeneous group of tumours with numerous morphological and molecular...
7.
Veyssiere H, Aldarazi G, Molnar I, Durando X, Radosevic-Robin N
Anticancer Res
. 2022 Jul;
42(7):3583-3594.
PMID: 35790290
Background: High-grade epithelial ovarian cancer (HGEOC) is a heterogeneous disease and among the deadliest types of cancer. It often acquires resistance to conventional chemotherapy and its prognosis remains highly poor....
8.
To N, Radosevic-Robin N, Belkacemi Y
Rep Pract Oncol Radiother
. 2022 Apr;
27(1):180-181.
PMID: 35402032
No abstract available.
9.
To N, Nguyen H, Thiolat A, Liu B, Cohen J, Radosevic-Robin N, et al.
Breast Cancer Res Treat
. 2022 Apr;
193(2):265-279.
PMID: 35397079
Purpose: Radiation therapy (RT) for triple-negative breast cancer (TNBC) treatment is currently delivered in the adjuvant setting and is under investigation as a booster of neoadjuvant treatments. However, TNBC radioresistance...
10.
Ferrand N, Fert A, Morichon R, Radosevic-Robin N, Zaoui M, Sabbah M
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326638
Vasculogenic mimicry (VM) formed by aggressive tumor cells to create vascular networks connected with the endothelial cells, plays an important role in breast cancer progression. WISP2 has been considered as...